Gentian Diagnostics ASA

Report Publication Announcement • May 24, 2019

Gentian hosted a successful workshop for Calprotectin at EuroMedLab 2019 in Barcelona

24th May 2019, Moss, Norway

Gentian Diagnostics AS is pleased to proclaim its successful participation at the 23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, EuroMedLab 2019 in Barcelona, Spain.

Plasma Calprotectin: a promising early biomarker for diagnosis of bacterial infections and sepsis

Gentian hosted the Educational Workshop "Plasma Calprotectin: a promising early biomarker for diagnosis of bacterial infections and sepsis.". The workshop was well attended, and two speakers were invited, Dr. Jordi Rello, MD, PhD (Spain) and Dr. Toralph Ruge, MD, PhD (Sweden). Dr. Aleksandra Havelka, PhD (Sweden) presented Dr. Ruge's talk.

The talks discussed calprotectin and other biomarkers' role in diagnosis of severe infections and sepsis. The presentations showed studies and results supporting the ability of calprotectin to discriminate patients with acute infections from patients with other states of inflammatory responses, including patients with heart failure, chronic obstructive pulmonary disease and asthma presented in the emergency department setting. Highlights include:

• Calprotectin is an independent predictor of 28-day mortality in septic patients and promising biomarker in early diagnosis, risk stratification, and evaluation of prognosis in septic patients¹
• Calprotectin is an accurate marker of sepsis in very low birth weight newborns²
• Calprotectin has significant diagnostic accuracy for the bacterial etiology of sepsis³

¹Gao, S. et al (2015) Am J Emerg Med 33 1278–1282 ²Terrin et al (2011), Clin Dev Immunol.; 2011:291085 ³Bartáková E.et al (2019) Diagnostic Microbiol Infect Dis, 219-226

Calprotectin acknowledged as a promising biomarker by the industry

Dr. Hilja Ibert, CEO of Gentian Diagnostics AS says; "We are pleased to have participated at EuroMedLab 2019. The high level of interest from the congress participants for our new GCAL biomarker has been encouraging. We feel confident in our strategic focus on innovations that improve laboratory and clinical efficiency." Dr. Erling Sundrehagen, CSO of Gentian Diagnostics AS continues: "I'm delighted to see the studies supporting calprotectin, and also the increased interest from the industry, both medical suppliers and clinicians".

For further information about the workshop, poster or our plasma calprotectin immunoassay, please contact:

Hilja Ibert CEO, Gentian Diagnostics AS E-mail: hilja.ibert@gentian.no +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics AS E-mail: njaal.kind@gentian.no +47 919 06 525